GlassScriptPhysician profile
Tobin Thoppil Abraham
NPI 1649683889
$25,075.70
in general payments reported to CMS, 2019-2025
30 companies · $4,699 in 2025
The $4,699 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,436 · 2021: $3,828 · 2022: $4,994 · 2023: $5,927 · 2024: $4,192 · 2025: $4,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $962 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,488.63 |
| Travel and Lodging | $961.95 |
| Education | $367.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,498.02 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $3,974.16 | 2020-2025 | Evenity, Tavneos, Krystexxa |
| Janssen Biotech, INC. | $2,684.30 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $1,661.83 | 2020-2024 | Taltz, Zepbound, Olumiant |
| Ucb, INC. | $1,480.51 | 2020-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,380.41 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,300.61 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,277.10 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,159.25 | 2020-2025 | Benlysta |
| Pacira Pharmaceuticals Incorporated | $1,134.75 | 2023 | Iovera |
| Mallinckrodt Hospital Products INC. | $1,007.38 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $989.55 | 2021-2025 | Lupkynis |
| Radius Health, INC. | $419.73 | 2022-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $356.87 | 2020-2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $288.03 | 2020-2025 | Strensiq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $282.38 | 2020-2025 | Gelsyn-3 |
| Genentech USA, INC. | $252.38 | 2020-2024 | Actemra |
| Horizon Therapeutics Plc | $228.53 | 2020-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $217.63 | 2023-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $153.29 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.48 | 2021-2022 | |
| Pacira Therapeutics, INC. | $62.75 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $47.43 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $41.32 | 2025 | Tremfya |
| Fresenius Kabi USA, LLC | $28.55 | 2023 | Idacio |
| Tonix Medicines, INC. | $18.54 | 2025 | Tonmya |
| Sanofi-Aventis U.S. LLC | $14.71 | 2020 | |
| Organon LLC | $14.30 | 2023 | Renflexis, Hadlima |
| Catalyst Pharmaceuticals, INC. | $13.97 | 2021 | |
| Sandoz INC. | $13.94 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobin Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.